NCT06935227 Steri-Strip Tape Use in Unilateral Ectropion Surgery
| NCT ID | NCT06935227 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Claudia Aristizábal |
| Condition | Ectropion |
| Study Type | INTERVENTIONAL |
| Enrollment | 74 participants |
| Start Date | 2025-05-01 |
| Primary Completion | 2026-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 74 participants in total. It began in 2025-05-01 with a primary completion date of 2026-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Currently, the incidence of involutional and chronic eyelid disorders, such as ectropion, has been increasing, as human life expectancy has risen worldwide (more than 600 million people are aged ≥ 60 years). Ectropion is a common eyelid malposition that causes visual morbidity. It is characterized by eversion of the eyelid margin and has multiple etiologies. Steri-Strip tapes have been used in some ophthalmologic procedures, such as blepharoplasties, where they help prevent infections by acting as a barrier method, are resistant enough to reduce the risk of wound dehiscence, simplify postoperative care, and allow for proper eyelid fissure closure. Their use has been recommended in patients with facial paralysis to prevent keratitis or exposure ulcers. However, current evidence is limited, as their use has only been documented in case series and letters to the editor. Therefore, a randomized controlled clinical trial is proposed to evaluate the postoperative outcomes of Steri-Strip tape use in unilateral ectropion surgery compared to standard postoperative management.
Eligibility Criteria
Inclusion Criteria: * Patients aged 18 years or older who are scheduled to undergo unilateral ectropion surgery. Exclusion Criteria: * Underlying conditions associated with skin hyperlaxity, such as cutis laxa and Ehlers-Danlos syndrome. * Skin diseases that predispose to cicatricial ectropion, such as ichthyosis, scleroderma, and psoriasis. * Paralytic ectropion. * Current use of oral isotretinoin.
Contact & Investigator
Tatiana Gomez, MD
PRINCIPAL INVESTIGATOR
Unisanitas
Frequently Asked Questions
Who can join the NCT06935227 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Ectropion. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06935227 currently recruiting?
Yes, NCT06935227 is actively recruiting participants. Contact the research team at jbenavidescr@unisanitas.edu.co for enrollment information.
Where is the NCT06935227 trial being conducted?
This trial is being conducted at Bogotá, Colombia.
Who is sponsoring the NCT06935227 clinical trial?
NCT06935227 is sponsored by Claudia Aristizábal. The principal investigator is Tatiana Gomez, MD at Unisanitas. The trial plans to enroll 74 participants.